Lv1
64 积分 2025-12-22 加入
Cost-effectiveness analysis of glofitamab versus rituximab for relapsed or refractory diffuse large B-cell lymphoma patients in China
3天前
已完结
Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study
10天前
已完结
Implementation of artificial intelligence approaches in oncology clinical trials: A systematic review
11天前
已完结
Overall Survival After Concurrent Cisplatin-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma
11天前
已完结
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
14天前
已完结
Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colorectal Cancer
15天前
已完结
Coalescing single-cell genomes and transcriptomes to decode breast cancer progression
15天前
已完结
Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma
1个月前
已完结
Treatment and Survival Outcomes in Follicular Lymphoma Patients with POD24: A Systematic Review and Meta-Analysis
1个月前
已关闭
Obinutuzumab‐related adverse events: A systematic review and meta‐analysis
1个月前
已完结
皖公网安备34019202002308
